The Technical Analyst
Sol Gel Technologies Ltd [SLGL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sol Gel Technologies Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.04% $0.900
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 25.07 mill |
| EPS: | -1.010 |
| P/E: | -0.890 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 27.86 mill |
| Avg Daily Volume: | 0.0322 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.890 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.890 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0555 (-93.83%) $-0.845 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.817 - 0.983 ( +/- 9.22%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.900
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.900
Forecast 2: 16:00 - $0.900
Forecast 3: 16:00 - $0.900
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.900 (5.04% ) |
| Volume | 0.0034 mill |
| Avg. Vol. | 0.0322 mill |
| % of Avg. Vol | 10.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLGL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 07:00:00 - Press Release
Sol-gel's Collaboration Partner First-to-file Anda Drug Product Generic To Zoryve® Cream
Ness ziona, israel, april 01, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%) for gorlin syndrome, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that padagis israel pharmaceuticals ltd (“padagis”), sol-gel's collaboration partner, submitted a first-to-file abbreviated new drug application (“anda”) to the u.s. food and drug administration (“fda”) for roflumilast cream, 0.3%, a drug product generic to zoryve® cream (roflumilast cream, 0.3%), indicated for the treatment of plaque psoriasis in patients six years of age and older.
2024-03-13 07:00:00 - Press Release
Sol-gel Reports Full-year 2023 Financial Results And Corporate Developments
An ongoing phase 3 clinical trial of sgt-610 for gorlin syndrome with the first patient screened; results are expected by the end of 2025 sol-gel maintains a cash runway into the second half of 2025 ness ziona, israel, march 13, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%), an orphan drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in gorlin syndrome and partnered with galderma to commercialize two approved large-category dermatology products, twyneo® and epsolay®, in the u...
2023-11-30 07:00:00 - Press Release
Sol-gel Technologies Screens First Patient For Sgt-610 Phase 3 Study
Ness ziona, israel, nov. 30, 2023 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl) (“sol-gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that it has begun phase 3 testing of sgt-610 (patidegib gel, 2%) for gorlin syndrome with the first patient screened. sgt-610 is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma (bcc) lesions in patients with gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. patidegib was acquired by sol-gel from pellepharm and is currently the only therapy in development to prevent the development of new bcc lesions in gorlin syndrome patients.
2023-11-28 08:06:00 - Press Release
Sol-gel Technologies Ltd To Host Virtual Kol Event On Gorlin Syndrome And The Upcoming Phase 3 Trial For Sgt-610
Ness ziona, israel, nov. 28, 2023 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl) (“sol-gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced it will host a virtual kol event on wednesday, december 6, 2023 at 12:00 pm et. to register, click here .
2023-11-09 07:00:00 - Press Release
Sol-gel Technologies Reports Third Quarter 2023 Financial Results And Provides Corporate Update
Ness ziona, israel, nov. 09, 2023 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl) (“sol-gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced financial results for the third quarter ended september 30, 2023 and provided a corporate update.
Latest News
2023-10-30 11:17:43 - Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
2023-08-30 08:00:00 - GlobeNewsWire
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
2023-08-10 10:01:29 - Zacks Investment Research
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.
2023-05-12 09:56:41 - Zacks Investment Research
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.
2023-03-20 07:00:00 - GlobeNewsWire
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright's Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.
2023-03-15 11:44:07 - InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
2023-03-10 09:57:36 - Zacks Investment Research
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.
2023-02-23 14:32:16 - InvestorPlace
The Top 7 Penny Stocks to Invest in for the Long-Term
Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investment.
2022-12-07 12:02:14 - Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Inflation Pressures
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
2022-11-10 08:17:12 - Zacks Investment Research
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.